Agilent makes investment in Lasergen
March 8th, 2016
Posted by Caroline Popper, M.D., M.P.H.
Agilent is investing $80 million in our client Lasergen, an emerging biotechnology company with innovative next-generation sequencing (NGS) technology. The two companies will collaborate on building a NGS solutions workflow for clinical applications, based on Lasergen’s Lightning Terminators™ sequencing chemistry.
This recent investment showcases the trend toward new players and innovative technology in the NGS space, particularly as the technology moves to more routine clinical use.
Lasergen’s relationship with Agilent is another example of how Popper and Company helps companies create transformative business partnerships.
Like this content? Don’t miss an update.